KR102307590B9 - Biomarker composition for drug resistance diagnosis and diagnostic kit using the same - Google Patents

Biomarker composition for drug resistance diagnosis and diagnostic kit using the same

Info

Publication number
KR102307590B9
KR102307590B9 KR1020200029633A KR20200029633A KR102307590B9 KR 102307590 B9 KR102307590 B9 KR 102307590B9 KR 1020200029633 A KR1020200029633 A KR 1020200029633A KR 20200029633 A KR20200029633 A KR 20200029633A KR 102307590 B9 KR102307590 B9 KR 102307590B9
Authority
KR
South Korea
Prior art keywords
same
drug resistance
diagnostic kit
biomarker composition
resistance diagnosis
Prior art date
Application number
KR1020200029633A
Other languages
Korean (ko)
Other versions
KR102307590B1 (en
KR20210114219A (en
Inventor
정재호
김정민
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to KR1020200029633A priority Critical patent/KR102307590B1/en
Priority to PCT/KR2021/002888 priority patent/WO2021182838A1/en
Publication of KR20210114219A publication Critical patent/KR20210114219A/en
Application granted granted Critical
Publication of KR102307590B1 publication Critical patent/KR102307590B1/en
Publication of KR102307590B9 publication Critical patent/KR102307590B9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020200029633A 2020-03-10 2020-03-10 Biomarker composition for drug resistance diagnosis and diagnostic kit using the same KR102307590B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020200029633A KR102307590B1 (en) 2020-03-10 2020-03-10 Biomarker composition for drug resistance diagnosis and diagnostic kit using the same
PCT/KR2021/002888 WO2021182838A1 (en) 2020-03-10 2021-03-09 Composition for diagnosing drug resistance and diagnosis kit using same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200029633A KR102307590B1 (en) 2020-03-10 2020-03-10 Biomarker composition for drug resistance diagnosis and diagnostic kit using the same

Publications (3)

Publication Number Publication Date
KR20210114219A KR20210114219A (en) 2021-09-23
KR102307590B1 KR102307590B1 (en) 2021-10-01
KR102307590B9 true KR102307590B9 (en) 2022-01-17

Family

ID=77671815

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200029633A KR102307590B1 (en) 2020-03-10 2020-03-10 Biomarker composition for drug resistance diagnosis and diagnostic kit using the same

Country Status (2)

Country Link
KR (1) KR102307590B1 (en)
WO (1) WO2021182838A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102668886B1 (en) * 2021-07-08 2024-05-24 연세대학교 산학협력단 A composition for treating drug resistance
KR20230119346A (en) * 2022-02-07 2023-08-16 한국화학연구원 TRIM51 biomarker for predicting melanoma treatment resistance and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636329B2 (en) 2012-11-06 2017-05-02 Northwestern University Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
KR20200044677A (en) * 2018-10-18 2020-04-29 (주)신테카바이오 Bio-Marker for Prediction of Drug Sensitivity, Estimation Method for Prediction of Drug Sensitivity and Diagnosing Chip for Prediction of Drug Sensitivity

Also Published As

Publication number Publication date
KR102307590B1 (en) 2021-10-01
WO2021182838A1 (en) 2021-09-16
KR20210114219A (en) 2021-09-23

Similar Documents

Publication Publication Date Title
SG11202112095VA (en) Microrna marker combination for diagnosing gastric cancer and diagnostic kit
PL413090A1 (en) Starters, method for microbiological analysis of biomaterial, application of the NGS sequencing method in microbiological diagnostics and the diagnostic set
EP2468776A3 (en) Anti-Robo4 antibodies and uses therefor
EP1937280A4 (en) Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
KR102307590B9 (en) Biomarker composition for drug resistance diagnosis and diagnostic kit using the same
EP4255276A4 (en) Medical diagnostic kit
EP4121558A4 (en) Rapid diagnostic test
EP3940404A4 (en) Battery resistance diagnosis device and method
KR200493591Y9 (en) Diagnostic kit tray
KR102258934B9 (en) Composition for diagnosis of Lyme disease and kit comprising the same
EP3956346A4 (en) Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
PL385415A1 (en) Method of bacterial resistance detection, diagnostic kit and application of the determination of presencea of the drug and/or products of its decomposition
IN2013CN02996A (en)
GB201816376D0 (en) Diagnostic test
WO2018236134A3 (en) Method and kit for diagnosis of muscle weakness-related diseases using blood biomarker
EP4060346A4 (en) Companion diagnosis biomarker composition and companion diagnosis kit containing same
KR102219895B9 (en) Composition for diagnosis of Tsutsugamushi disease and kit comprising the same
EP4069272A4 (en) Oligopeptide, testing kit thereof, medical composition thereof and use of medical composition
EP4077710A4 (en) Methods and compositions for monitoring and diagnosing healthy and disease states
EP3808858A4 (en) Biomarker for predicting effectiveness for autoimmune disease treatment, diagnostic kit, and use for treatment
PT3794148T (en) Diagnostic blood test
GB202012326D0 (en) Diagnostic
EP3851127A4 (en) Composition for detecting hydrogen sulfide or measuring hydrogen sulfide concentration and composition comprising same as effective ingredient for diagnosing or imaging in vivo inflammation, tissues having hypoxic damage, or cancer
GB2606734B (en) Diagnostic testing
EP3773553A4 (en) Formulations and kits for radiotherapy and diagnostic imaging

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Publication of correction